Unit of Infectious Diseases, “Divisione A”, Amedeo di Savoia Hospital, 10149 Torino, Italy
Elena Ricci
Fondazione ASIA Onlus, 20090 Buccinasco, Italy
Barbara Menzaghi
Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, 21052 Busto Arsizio, Italy
Giuseppe Vittorio De Socio
Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, 06129 Perugia, Italy
Nicola Squillace
Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, 20126 Monza, Italy
Giordano Madeddu
Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
Francesca Vichi
Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, 50012 Florence, Italy
Benedetto Maurizio Celesia
Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, 95123 Catania, Italy
Chiara Molteni
Infectious Diseases Unit, Ospedale A. Manzoni, 23900 Lecco, Italy
Federico Conti
Infectious Diseases Unit, Department of Biomedical and Clinical Sciences “Luigi Sacco”, Università Degli Studi di Milano, 20122 Milan, Italy
Filippo Del Puente
Department of Health Sciences, Infectious Disease Clinic, University of Genoa, 16145 Genoa, Italy
Eleonora Sarchi
Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, 15121 Alessandria, Italy
Goffredo Angioni
Infectious Diseases Unit, SS Trinità Hospital, 09121 Cagliari, Italy
Antonio Cascio
Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy
Carmela Grosso
Unit of Infectious Diseases, Cesena Hospital, 47521 Cesena, Italy
Giustino Parruti
Infectious Diseases Unit, Pescara General Hospital, 66020 Pescara, Italy
Antonio Di Biagio
Department of Health Sciences, Infectious Disease Clinic, University of Genoa, 16145 Genoa, Italy
Paolo Bonfanti
Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, 20126 Monza, Italy
The purpose of this study is to evaluate the frequency of central nervous system adverse events (CNS-AE) on dolutegravir (DTG) and non-DTG containing ART, and their reversibility, in the observational prospective SCOLTA cohort. Factors associated with CNS-AE were estimated using a Cox proportional-hazards model. 4939 people living with HIV (PLWH) were enrolled in DTG (n = 1179) and non-DTG (n = 3760) cohorts. Sixty-six SNC-AE leading to ART discontinuation were reported, 39/1179 (3.3%) in DTG and 27/3760 (0.7%) in non-DTG cohort. PLWH naïve to ART, with higher CD4 + T count and with psychiatric disorders were more likely to develop a CNS-AE. The risk was lower in non-DTG than DTG-cohort (aHR 0.33, 95% CI 0.19–0.55, p p = 0.017). In conclusion, CNS-AE leading to ART discontinuation was more frequent in DTG than non-DTG treated PLWH. Most CNS-AE resolved after ART switch, similarly in both DTG and non-DTG cohorts.
